Meet Our Target (MOT)

- Experience Sharing from Peking University Shenzhen Hospital on Passing CIHA International Hospital Accreditation and ISO 15189:2022 Accreditation by Professor JI Ling (北京大学深圳医院检验科主任) [Lecture to be conducted in Mandarin] - Beyond Compliance: Advancing ISO 15189:2022 with Unity Real Time by Mr. Nico VANDEPOELE (Global Scientific Affairs Manager, Bio-Rad Laboratories)

To obtain credit: 1. Watch the video. 2. Complete the posttest and evaluation that launches immediately following the video. 3. Generate and print your certificate. Deadline 12/05/2028

單元二由三個部份組成，內容涵蓋與《強制舉報虐待兒童條例》相關的法律和舉報事宜的基本知識。為了讓參加者可以循序漸進完成學習，單元二分為甲部、乙部及丙部。 以廣東話為教學語言，並附有三種字幕［中文（繁）、中文 （簡）或英文］可供選擇。 課程內容 甲部 - 《強制舉報虐待兒童條例》的主要規定 乙部 - 常見情境分析及簡介《強制舉報者指南》 丙部 - 舉報流程及舉報後的跟進

Abstract Clinical microbiology laboratories are under increasing pressure to deliver accurate, clinically meaningful antimicrobial susceptibility results while managing staffing constraints, rising test volumes, and ongoing demands for stewardship. Although many laboratories use a single automated ID/AST platform, variations in FDA cleared antimicrobial menus, performance characteristics, and reporting capabilities can create gaps that require additional offline testing—adding time, labor, and cost. In this session, Dr. Margie Morgan, an experienced clinical microbiologist and laboratory leader, will discuss how implementing a coexistence strategy across multiple ID/AST systems can help laboratories enhance the completeness and reliability of their reporting. She will outline how coexistence can reduce reliance on supplemental methods, better support CLSI recommended testing and reporting practices, and provide more comprehensive susceptibility data for patient management. Topics will include: • Why coexistence can be beneficial: platform differences, antibiotic coverage, clinical needs, and stewardship priorities. • The real cost of offline testing: labor, budget, turnaround time, and impact on patient management. • Ensuring appropriate reporting: understanding FDA clearance, recognizing when confirmation is required, and avoiding “reporting straight from the instrument.” • How a coexistence strategy can support accurate MIC reporting and reduce unnecessary testing burdens. Join us to explore how a “House United” approach can strengthen laboratory performance and ensure the right data is delivered to the right patient at the right time. Leaning Objectives: Describe CLSI recommended considerations for antimicrobial susceptibility testing and reporting, including when confirmation or supplemental methods are required. Identify how differences in FDA cleared antimicrobial menus across ID/AST systems influence reporting workflows and discuss strategies to ensure reliable, clinically appropriate susceptibility results. Evaluate how coexistence of multiple ID/AST systems can reduce offline testing, increase reporting completeness, and support laboratory workflow efficiency.

Description This webinar will examine the increasing prevalence of MASLD and MASH in the United States and the challenges that often lead to delayed and missed diagnoses. Attendees will gain insights into the evolving role of noninvasive blood-based biomarker testing for MASLD and MASH in supporting risk stratification and informing management decisions. Dr. Meena Bansal of Mount Sinai Health System will share real-world perspectives on the importance of incorporating these guideline-recommended biomarker tests into diagnostic and prognostic algorithms. Deadline 30/05/2027

Description Effective management of bleeding and coagulopathy requires timely and comprehensive assessment of hemostasis. Traditional coagulation tests provide limited information about the dynamic process of clot formation and platelet contribution to clot strength. Viscoelastic testing offers a whole-blood evaluation of clot development, while platelet function assays provide additional insight into platelet-mediated clot stability. This webinar will: Provide an overview of viscoelastic testing principles Explore how platelet function testing can complement these technologies for a more complete assessment of hemostasis Discuss the role of laboratory testing in supporting clinical decision-making Highlight ways to improve collaboration between laboratory and clinical teams Offer practical insights on integrating testing approaches to support comprehensive hemostasis assessment Deadline 30/04/2027

Abstract SPECIAL EDUCATIONAL WEBINAR IN HONOR OF 2026 MEDICAL LABORATORY PROFESSIONALS WEEK Coagulation testing is a critical component of patient care across multiple clinical settings. However, it is often affected by miscommunication, pre-analytical challenges, and gaps in understanding related to test selection, medication effects, and workflow limitations. Drawing from real-world experiences in the laboratory and interdisciplinary collaboration, this presentation explores common scenarios where misalignment between test ordering, specimen integrity, and clinical intent leads to delays or confusion. Attendees will gain practical strategies to improve communication, set appropriate expectations, and leverage the laboratory as a collaborative partner in coagulation testing and patient care. Objectives Identify common communication challenges surrounding coagulation test ordering, specimen quality, and result interpretation. Recognize frequent pre-analytical issues that lead to specimen rejection and workflow disruption in coagulation testing. Apply practical communication strategies to improve collaboration between the laboratory, clinicians, and pharmacy.

單元一涵蓋保護兒童的基本知識，旨在提升參加者及早識別和處理懷疑虐待兒童個案的能力。

記得入到去個Virtual Event 2026 要搵番個對應名稱(What Should Regulated Laboratories Consider When Going to the Cloud?) 嘅webinar黎睇, 唔係嘅話唔算架

Abstract Freeze drying doesn't have to be complicated. In this webinar, we break down the lyophilization process into clear, practical steps so you can get reliable results with confidence. You'll gain a practical understanding of the freeze drying process, from pre-freezing through primary and secondary drying, as well as how each stage impacts sample integrity. Whether you're new to freeze drying or want a quick refresher, this session will give you a solid foundation. Learning Objectives: The science behind freeze drying and why it matters Best practices to protect sample integrity Common mistakes and how to avoid them Learn about Labconco's scientific equipment offerings

Abstract The global spread of Highly Pathogenic Avian Influenza (HPAI), particularly the H5N1 2.3.4.4b clade, underscores the urgent need for rapid antibody development and characterization. Because the Hemagglutinin (HA) protein is structurally complex and undergoes continual antigenic drift, researchers must continually develop and screen hundreds of hybridomas to identify candidates with the necessary specificity and activity. In this webinar, we present an end-to-end characterization workflow using Bio-Layer Interferometry (BLI) to accelerate early selection decisions. Using a recombinant HA trimer as a model immunogen, we demonstrate how the Octet® system enabled high-throughput triage antibodies directly from crude, unpurified conditioned hybridoma media. We show how rapid titer estimation and off-rate ranking can be used to efficiently narrow large antibody panels without prior purification. We also highlight automated epitope binning to organize candidates into epitope families based on competitive binding behavior, ensuring epitope diversity among selected leads. By combining binning data with cross-reactivity assessments against related antigens, this workflow enables the rapid transition from a large pool of raw hybridoma candidates to a refined subset of high-value antibodies suitable for downstream therapeutic or diagnostic development. Learning Objectives: Perform comprehensive characterization: Early evaluation of titer, binding kinetics, and epitope binning identifies non-competing monoclonal antibodies for therapeutic development. Master Advanced screening: Using the Octet® RH96 platform for label-free biolayer interferometry (BLI), the study enables real-time assessment of antibody libraries, even with crude or unpurified samples. Optimize Automation and efficiency: The Biosero® GoSimple™ workcell automates high-throughput screening, allowing unattended operation for maximum productivity.

Key learning objectives: Describe the key physiological developmental processes that produce age- and sex-specific variation in pediatric biochemical analytes, and identify at least two such developmental factors. Differentiate between conventional and indirect methodologies for establishing pediatric reference intervals and explain how indirect data driven approaches more accurately support clinical interpretation of pediatric laboratory results. Evaluate the ethical and operational constraints associated with collecting pediatric reference samples and propose at least one evidence-based, data-driven strategy to mitigate these limitations within clinical laboratory practice.

Key learning objectives: Describe the role of the microbiology laboratory in guiding AST for critically ill patients. Recognize the value of accurate MIC data in improving turnaround times, optimizing therapy, and supporting new antibiotic use. Identify how antimicrobial stewardship programs rely on timely diagnostic data and collaboration to improve patient outcomes. Discuss the importance of multidisciplinary collaboration among microbiologists, clinicians, stewardship teams, and policymakers to combat antibiotic resistance in a post-Covid world.

Please submit the completed answer sheet within the specified validity period by email to hepatitis@dh.gov.hk.

Description This webinar showcases finalist teams from the 2025 ADLM Data Science Challenge, LabDocs Unlocked, who developed generative AI tools to extract information from complex laboratory document stores. Through live demonstrations and competition, participants will observe how different LLMs (e.g., GPT, Gemini, DeepSeek, AWS Nova, Grok) perform in a real laboratory application using retrieval-augmented generation. Presentations will highlight design decisions related to local deployment, data security, explainability, and integration into laboratory workflows. By directly comparing approaches and engaging the audience through interactive scoring or voting, the session reinforces best practices in laboratory data science while helping participants develop the judgment needed to select and apply generative AI tools responsibly in their own institutions.

Description Join us for an insightful webinar exploring patient safety risks and potentially fatal outcomes, due to undetected hemolysis at the point of care (POC). This webinar will cover patient cases where undetected hemolysis caused adverse patient outcomes, and will highlight how undetected hemolysis is exacerbated by insufficient awareness of blood gas testing limitations related to hemolysis. The importance of adopting solutions with integrated hemolysis detection to prevent these potential high-risk situations will be emphasized. Through expert-led discussions and actionable frameworks, attendees will learn how to adopt and scale technologies that drive efficiency across diverse hospital environments. Whether you're navigating resource constraints or planning future growth, this session offers practical guidance to strengthen your lab’s impact and resilience.

Abstract Mixing studies have traditionally been used to differentiate factor deficiencies vs. inhibitors. To kick-start, we will provide a historical overview of how mixing studies were instrumental for the discovery of coagulation factors. Although this test has been used for decades, it lacks standardization due to the variable sensitivity of PT and APTT reagents to factor deficiencies and non-specific inhibitors, such as drugs and lupus anticoagulants (LA). We will discuss advantages and disadvantages of recommended methods to interpret mixing studies (correction into the reference range, percentage correction, the Rosner index, and the estimated factor correction). We will compare the accuracy of these cut-off methods by providing examples of single factor deficiency vs. conditions associated with multiple factor deficiency. Lastly, we will discuss the use of mixing studies to detect inhibitors, including LAs. We will then dive into the debate of incorporating mixing studies in LA algorithms and the need for standardization of LA interpretation guidelines will be illustrated with interesting cases. Objectives Evaluate methods to determine correction on a 1:1 mix study Illustrate limitations of these cut-off methods for conditions involving multiple factor deficiencies Discuss the use of mixing study to interpret lupus anticoagulant testing

Abstract The signs and symptoms of Vitamin B12 deficiency are many but both variable and hard to identify as B12 deficiency. Traditional markers such as anemia or macrocytosis frequently fail to appear, especially when folate intake is high, allowing deficiency to progress silently for years. Many patients may have B12 deficiency for years without being diagnosed, yet the early diagnosis of B12 deficiency is crucial to prevent irreversible neurological damage.1,2 In this webinar Dr. Ralph Green, Distinguished Professor, University of California, Davis will share his insights on the changing landscape of Vitamin B12 deficiency and path towards a clinically meaningful approach to diagnosing vitamin B12 deficiency highlighting the limitations of traditional serum B12 tests. The speaker will focus on newer tests such as Active B12 (holotranscobalamin), considered a more sensitive and clinically useful biomarker than total serum B12 for diagnosing vitamin B12 deficiency—especially in detecting early neurological impairment. Learning Objectives Understand the association between Vitamin B12 deficiency, neurological disease, depression, fatigue and anaemia Significance of new tests such as Active B12 can lead to improved clinical outcomes.

Learning Objectives: Understand the stages of a standard RNA-seq bioinformatics workflow, including the role of QC, alignment, gene expression quantification, and specialized application analyses Identify key QC metrics in RNA-seq analysis and understand what those metrics represent in terms of data characteristics Recognize when fusion detection and splicing analyses are applicable and understand the structure of their output files RNA sequencing (RNA-seq) is a Next-Generation Sequencing (NGS) application for transcriptome profiling. This essential tool enables researchers to derive biological insights by investigating gene expression patterns, identifying novel transcripts, detecting alternative splicing events, and discovering gene fusions. However, analysis of RNA-seq data involves complex computational processes with comprehensive quality-control (QC) requirements; these can be challenging for researchers with limited experience in bioinformatics. This educational webinar provides a comprehensive overview of RNA-seq data analysis. The session covers the standard RNA-seq bioinformatics workflow we used to evaluate libraries prepared using the KAPA RNA EvoPrep Kit, showing how raw sequencing data progresses through quality assessment, read alignment, gene expression quantification, and specialized application analyses. Attendees will learn the technical definitions of key QC metrics and what they represent in the context of RNA-seq data characteristics. The webinar also introduces specialized application analyses including fusion detection and splicing analysis. For each application, attendees will learn relevant use cases and how to understand the structure and content of key results files.

Abstract Antigen-specific T cell populations are of great value for studying immune recognition but tedious to generate by limiting dilution or cloning. Here, we develop a streamlined approach to generate antigen-specific T cell clones from peripheral blood using the cloneXplorer, a live-cell analysis and clone isolation platform. This platform monitors cell proliferation, cytokine secretion, and surface markers in up to 100,000 single cell co-cultures, enabling the identification and recovery of rare, functionally defined T cells, for clonal expansion or sequence analysis. First, we show this platform can efficiently generate monoclonal cell populations from cell lines and primary T cells. Next, we demonstrate that antigen-specificity can be identified at single cell resolution in a co-culture of Jurkat cells expressing NFAT-GFP, CD8, and a T cell receptor and K562 antigen presenting cells expressing a peptide library. Thereafter, we show that immune activation in mouse and human primary samples can be monitored by time lapse analysis of IFN-γ secretion in individual microwell co-cultures. Finally, we combine these capabilities in a proof-of-concept demonstration, which uses IFN-γ secretion and the presence of CD8 markers as hierarchical gates to isolate and expand antigen-specific T cells from human peripheral blood, and we verify their specificity by tetramer staining.

Abstract mRNA technologies have rapidly evolved into one of the most exciting and versatile classes of modern medicines, powering breakthroughs in vaccines and emerging therapies for metabolic, cardiovascular, and oncology applications. But as the field accelerates, so does the need for deeper insight into the quality and structural integrity of mRNA products. Throughout manufacturing, purification, formulation, and storage, mRNA molecules can develop impurities such as double stranded RNA, truncated transcripts, and higher order multimers. These species can reduce translational efficiency, hinder effective lipid nanoparticle encapsulation, and ultimately compromise product safety and performance. Yet many conventional analytical tools rely on denaturing conditions, making it difficult to detect and quantify these structures in their native state. In this webinar, Mark Dickman, Professor at the University of Sheffield, explores how mass photometry, a label free, single molecule analytical technology, is reshaping mRNA characterization. Professor Dickman will highlight how combining non‑denaturing ion‑pair reversed phase HPLC (IP RP HPLC) with mass photometry enables precise measurement of mRNA monomers and multimers directly in solution—providing accurate insights into size, purity, and aggregation under native conditions. Join us to learn how this innovative approach can enhance your ability to assess critical quality attributes and support the development of safer, more effective mRNA based therapeutics.

Abstract Have you ever struggled to accurately pipette glycerol, ethanol, or other challenging liquids? METTLER TOLEDO Rainin developed Good Pipetting Practice™ (GPP™) as a practical, science-based approach to help scientists improve the accuracy and efficiency of their experiments. In this GPP webinar, we will discuss different classes of liquids and how to get the best performance out of your pipettes. Most pipettes are optimized for room temperature liquids with properties similar to water so accurately pipetting viscous, high vapor pressure, low surface tension, hazardous, non-room temperature or foaming liquids requires careful adjustments. Each of these properties influence the optimal pipette type and technique to ensure accuracy and reproducibility with these challenging liquids. Learning Objectives: Outline the classes of challenging liquids and their properties Select the optimal pipettes for different liquids Identify pipetting techniques that can improve accuracy

Abstract The generation of durable CD8+ T cell memory following infection or vaccination is essential for protection against future encounters with the same or related pathogens. This process has traditionally been viewed as dependent on CD4+ T cell help. However, in many acutely resolving infections, memory CD8+ T cells can form even in the absence of CD4+ T cell support. Despite their formation, these so-called “helpless” memory CD8+ T cells often exhibit reduced protective capacity upon secondary immune challenge. These apparent contradictions raise fundamental questions about how “helpless” memory CD8+ T cells arise, how stable they are over time, and what constrains their functional potential. In this webinar, we will present recent work examining the development and long-term fate of “helpless” memory CD8+ T cells across multiple murine infection models. We will show that early CD8+ T cell responses can initially appear intact without CD4+ T cell help, yet prolonged exposure to residual antigen transiently compromises the quality and function of the memory CD8+ T cell pool. Finally, we will demonstrate how these defects resolve over time, uncovering unexpected plasticity within the memory CD8+ T cell compartment and offering important insights for vaccine design and immune-based interventions. Key topics discussed in this webinar will include: The role of CD4+ T cells in shaping the quality and durability of CD8+ T cell memory The impact of ongoing antigen exposure on the functional capacity of memory CD8+ T cells The use of cell sorting, adoptive cell transfer, and spectral flow cytometry to analyze CD8+ T cell memory formation during acutely resolving infections

Abstract In this webinar, discover how high-sensitivity multiplex protein analysis enables comprehensive profiling of 45 immune biomarkers, spanning cytokines, chemokines, and key immune mediators, from minimal sample volumes. This powerful approach supports true longitudinal mouse studies, reduces variability, preserves precious samples, and promotes more ethical research design. We will showcase its application in immuno-oncology through the in vivo characterization of a next-generation, detoxified TLR4 agonist engineered for safe systemic delivery. By mapping immune activation dynamics across tissues and time, this strategy reveals how TLR4 signalling pathways drive antitumor responses—providing actionable mechanistic insights to guide therapeutic development. Join us to learn how advanced, high-resolution cytokine profiling can accelerate translational research and strengthen your immuno-oncology and inflammation studies. Learning Objectives: Learn how high-sensitivity multiplex protein analysis enables comprehensive immune profiling from just 1 µL of mouse sample. Understand how detoxified TLR4 agonists activate innate and adaptive immunity through MyD88 and TRIF pathways. Apply these mechanistic insights to advance safer, systemically deliverable TLR4‑based immunotherapies.

Description Hospital systems today face mounting pressure to deliver high-quality care amid staffing shortages, rising test volumes, and operational inefficiencies. This webinar addresses the urgent need for scalable solutions by exploring real-world challenges and showcasing proven strategies in lab automation, digital workflow design, and system-wide optimization. Participants will gain insights into how leading institutions are transforming diagnostics to improve throughput, reduce burnout, and elevate patient outcomes. Through expert-led discussions and actionable frameworks, attendees will learn how to adopt and scale technologies that drive efficiency across diverse hospital environments. Whether you're navigating resource constraints or planning future growth, this session offers practical guidance to strengthen your lab’s impact and

Abstract Autoantibody testing plays a critical role in diagnosing autoimmune diseases, yet it remains one of the most complex and variable areas in clinical diagnostics. This webinar will focus on the unique challenges and best practices in proficiency testing (PT)/external quality assessment (EQA) for autoantibody assays and will explore how PT/EQA contributes to analytical accuracy, supports regulatory compliance, and drives continuous quality improvement in autoimmune diagnostics. Attendees will learn how to interpret PT/EQA results, implement corrective actions, and navigate common pitfalls specific to autoantibody testing. Through real-world case studies and role-specific insights, participants will leave with actionable strategies to strengthen their lab’s performance and build confidence in autoantibody testing for optimal patient care. Learning Objectives Recognize the importance of PT/EQA for maintaining clinical assay consistency and laboratory quality List regulatory requirements for PT/EQA for clinical laboratory testing Analyze PT/EQA data and investigate failures for the purpose of optimizing assay performance

Abstract Liquid biopsy (LBx) has emerged as a non-invasive genomic profiling approach to guide decision-making and to monitor resistance in cancer, especially when access to tumor tissue is limited. However, one of the key challenges of LBx is distinguishing somatic variants from clonal hematopoiesis (CH)-derived variants, which can occur in biologically relevant genes and confound variant interpretation. In this webinar, Dr. Keller and Dr. Fares (IUCT Oncopole, France) will explore real-world cases where insights from MSK-ACCESS® powered with SOPHiA DDM™ helped inform decisions. The decentralized liquid biopsy solution integrates matched white blood cell (WBC) DNA sequencing to filter out CH and germline variants, increasing confidence in the somatic origin of detected alterations. By attending this session, you will gain: Practical insights into the clinical utility of liquid biopsy An understanding of how CH confounds variant interpretation Real-world examples of how matched tumor-normal analysis helps inform decision-making

Abstract Liquid biopsy has emerged as a revolutionary technology in the precision medicine field, by offering a non-invasive alternative to traditional tumor biopsies. While its potential for tumor detection and monitoring continues to grow, global adoption remains limited due to technical, workflow, and access-related barriers.​ In a leading partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through the deployment of MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay. ​ Join this insightful workshop to explore how a decentralized approach enables broader patient access to testing and accelerates pharmaceutical development, setting new standards in precision oncology. In this session you will:​ Discover how SOPHiA GENETICS advanced analytics enables scalable, robust, and reproducible liquid biopsy testing, through its decentralized approach, supported by large-scale evidence generation studies across local deployments.​ Gain insights into the clinical impact and utility of adopting MSK-ACCESS® powered with SOPHiA DDM™, and how it improves access and outcomes for cancer patients.​ Explore how decentralized testing strategies support late-stage pharmaceutical development and drive commercial success in precision medicine.​